BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 1999656)

  • 1. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
    von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
    Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.
    Cheung AK; Parker CJ; Wilcox L
    Clin Exp Immunol; 1989 Nov; 78(2):299-306. PubMed ID: 12412765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
    Eggertsen G; Lundwall A; Hellman U; Sjöquist J
    J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular cloning and characterization of a complement-depleting factor from king cobra, Ophiophagus hannah.
    Zeng L; Sun QY; Jin Y; Zhang Y; Lee WH; Zhang Y
    Toxicon; 2012 Sep; 60(3):290-301. PubMed ID: 22561424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
    Till GO; Morganroth ML; Kunkel R; Ward PA
    Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naja melanoleuca cobra venom contains two forms of complement-depleting factor (CVF).
    Osipov AV; Mordvintsev DY; Starkov VG; Galebskaya LV; Ryumina EV; Bel'tyukov PP; Kozlov LV; Romanov SV; Doljansky Y; Tsetlin VI; Utkin YN
    Toxicon; 2005 Sep; 46(4):394-403. PubMed ID: 16054663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of three medically important Nigerian Naja (Naja haje, Naja katiensis and Naja nigricollis) snake venoms.
    Adamude FA; Dingwoke EJ; Abubakar MS; Ibrahim S; Mohamed G; Klein A; Sallau AB
    Toxicon; 2021 Jul; 197():24-32. PubMed ID: 33775665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of therminal components of human complement by a trypsin-activated complex of human factor B and cobra venom factor.
    Miyama A; Kato T; Minoda I; Ueda T; Kashiba S
    Jpn J Microbiol; 1976 Dec; 20(6):507-16. PubMed ID: 1035353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
    Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
    Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.